Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease and Oncology Development.
Target Overview: Structure, Domains, and Key Mutations
AKT2 (PKBβ) is a serine/threonine protein kinase belonging to the AGC kinase family. Its functional domains include:
- PH (Pleckstrin Homology) domain – essential for membrane recruitment via PIP3 binding.
- Protein kinase domain – catalytic core for substrate phosphorylation.
- AGC-kinase C-terminal domain – regulatory region controlling activation and stability.
Key mutations relevant to drug resistance and isoform selectivity:
- E17K (in HIHGHH; exhibits plasma membrane localization in serum-starved cells) – constitutive membrane association, confers resistance to PH-domain inhibitors.
- rs55859611 (dbSNP) – a missense variant with potential impacts on kinase activity.
- rs35817154 (dbSNP) – another reported variant; functional consequences under investigation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AKT2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-type) | AKT2 Recombinant Kinase Domain High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. ATP-binding site intact. |
View AKT2 Products |
| Antigen (Mutant) | AKT2 E17K Constitutively Active Mutant Sequence Verified. Theoretical MW confirmed. For resistance mechanism studies. |
View AKT2 Products |
| Gene Delivery | AKT2 Promise-ORF / Lentivirus Full-length ORF with myristoylation site for stable cell lines. HEK293 Expressed. |
View AKT2 Products |
| Benchmark Ab | Anti-AKT2 (Clone for Pathway Analysis) Recombinant monoclonal for Western/ELISA control. |
View AKT2 Products |
| Validator | AKT2 siRNA Set (3 unique sequences) For knockdown verification and specificity confirmation. |
View AKT2 Products |
| Related Target: AKT1 | AKT1 (PKBα) Paralog kinase for selectivity counter-screening. >95% purity. |
View AKT1 Products |
| Related Target: AKT3 | AKT3 (PKBγ) Paralog kinase for pan-AKT vs isoform-specific assay design. |
View AKT3 Products |
| Related Target: PIK3CA | PIK3CA (p110α) Upstream activator. Partner for pathway combination studies. |
View PIK3CA Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (AKT1/AKT2/AKT3) | Human AKT1, AKT2, AKT3 Kinase Domains available as separate lots with >95% purity. Sequence verified distinct epitopes for antibody selectivity testing. |
| Drug Resistance Mutations (E17K, etc.) | Mutant AKT2 proteins (E17K, L52R) with sequence-verified mutations. Endotoxin controlled for cellular assay compatibility. |
| ATP-competitive vs Allosteric Screening | Wild-type and mutant proteins retain native ATP-binding pocket conformation. Suitable for FP, TR-FRET, and SPR assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Pathway-grade) and Active Kinase positive controls included. |
| False Positives | Validated siRNA included for specificity checks in cellular context. |
TarMart also provides human/mouse/cyno ortholog proteins for cross-species studies, enabling seamless translation from preclinical models to human assays.
Live AKT2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AKT2-targeted therapeutics is intensifying, with major players shifting focus from pan-AKT small molecule inhibitors to isoform-selective allosteric modulators and PROTACs. First-generation pan-AKT therapies (e.g., capivasertib) face dose-limiting metabolic toxicities, primarily hyperglycemia driven by AKT1 inhibition and insulin resistance exacerbated by AKT2 blockade. The next wave of R&D aims to circumvent these toxicities through selective targeting of AKT2’s pleckstrin homology (PH) domain or allosteric sites distinct from the ATP-binding pocket. In oncology, AKT2 amplification and aberrant activation define responder populations, while in metabolic disease, AKT2’s central role in insulin-stimulated GLUT4 translocation makes it a key node for type 2 diabetes and metabolic syndrome. Over the next 3–5 years, we anticipate an expanding pipeline of AKT2-biased agents, accompanied by demand for sophisticated isoform selectivity assays, resistance mutation profiling, and cross-species reagents. The emergence of PROTAC degraders and RNAi-based modalities further diversifies the therapeutic landscape, promising to address both kinase-dependent and scaffolding functions of AKT2.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | AstraZeneca, Roche, Preclinical biotechs | Advanced Solid Tumors, Breast Cancer, Type 2 Diabetes | Conformational selectivity assay (need high-purity AKT1/2/3 proteins; full-length constructs with intact PH domain) |
| Small Molecule (ATP-competitive) | Novartis, Eli Lilly, Merck | Solid Tumors, PIK3CA/PTEN mutated cancers | Kinase activity assay (need active AKT2 with correct phosphorylation status; mutant proteins for resistance profiling) |
| PROTAC / Degrader | Arvinas, C4 Therapeutics, Emerging Biotechs | Drug-resistant carcinomas, Refractory cancers | Ternary complex validation (need full-length AKT2 + E3 ligase reagents; degradation monitoring antibodies) |
| siRNA / ASO | Alnylam, Ionis | Metabolic Disorders, Liver Disease | Knockdown validation (need sequence-verified siRNAs; AKT2-specific antibodies for readout) |
Conclusion
As the field moves toward precision targeting of AKT isoforms, high-quality reagents that enable accurate isoform selectivity assessment, mutation screening, and mechanistic studies are indispensable. TarMart’s portfolio—covering wild-type and mutant AKT2 proteins, validated antibodies, siRNA controls, and related pathway targets—provides the foundational tools to accelerate AKT2 drug discovery from bench to clinic.